RNS Number : 6389U
Bioquell PLC
19 May 2008
TO: CITY EDITORS
FOR IMMEDIATE RELEASE
19 May, 2008
BIOQUELL PLC
Interim Management Statement
(BIOQUELL PLC is publishing this announcement pursuant to the UK Listing Authority's
Disclosure and Transparency Rules which revised and
added to the requirements on periodic financial reporting for UK listed companies, including
the requirement for Interim Management
Statements to be issued twice a year.)
BIOQUELL PLC ("BIOQUELL") (LSE symbol: BQE), the UK leader in specialist decontamination
technology and testing/compliance services,
announces its Interim Management Statement for the period from 1 January, 2008 to 19 May,
2008.
Financial position and performance of the Company
Group revenues in the first four months of the year were in line with the Board's
forecasts and above the same period last year.
The Group has seen increased interest, in the UK and internationally, in the use of its
hydrogen peroxide vapour ("HPV") decontamination
technology to combat hospital acquired infection / "superbugs" contaminating healthcare
equipment and facilities. BIOQUELL is considering a
number of ways to accelerate the international roll out of its unique HPV technology in the
healthcare sector. Good progress has also been
made on collaborative academic research demonstrating further the key role of the hospital
environment in the spread of certain
"superbugs".
HPV equipment sales to the life sciences sector have shown strong growth in the period.
The Group continues to make good progress in expanding its activities and product range in
the defence sector, particularly in the
United States.
Trading in the TRAC division has been broadly flat - with some businesses showing robust
growth and others showing a reduction, although
a significant element of this reduction relates to disruption from a facility move which
started at the end of 2007 and carried on into the
first quarter of 2008.
The Group's balance sheet remains strong - with the net cash position increasing
significantly since the year end.
Enquiries
John Salkeld BIOQUELL PLC 01264 835 900
Nick Adams
Mark Bodeker
This information is provided by RNS
The company news service from the London Stock Exchange
END
IMSAFMMTMMBBBBP
|